{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:51:58Z","timestamp":1785891118948,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jconrel.2022.07.035","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T18:42:23Z","timestamp":1659465743000},"page":"783-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma"],"prefix":"10.1016","volume":"349","author":[{"given":"Md Nurul","family":"Huda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac G.","family":"Deaguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar A.","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamanna","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humayra","family":"Afrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Varela-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato J.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden E.L.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Nurunnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.07.035_bb0005","author":"American Cancer Society"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0010","author":"American Cancer Society"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(05)17951-3","article-title":"Cutaneous melanoma","volume":"365","author":"Thompson","year":"2005","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2004.05708.x","article-title":"Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma","volume":"150","author":"Lens","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1055-9965.EPI-04-0632","article-title":"Risk factors for melanoma by body site","volume":"14","author":"Cho","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0030","first-page":"228","article-title":"Melanoma: molecular pathogenesis and therapeutic management","volume":"6","author":"Liu","year":"2014","journal-title":"Mol. Cell. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yadr.2007.07.015","article-title":"Growth factors and oncogenes as targets in melanoma: lost in translation?","volume":"23","author":"Kwong","year":"2007","journal-title":"Adv. Dermatol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0040","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12837.1","article-title":"Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas","volume":"7","author":"Christensen","year":"2018","journal-title":"F1000Research."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.addr.2020.05.011","article-title":"Nanoparticles for topical drug delivery: potential for skin cancer treatment","volume":"153","author":"Krishnan","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0050","first-page":"979","article-title":"Hydroquinone","author":"Gad","year":"2014","journal-title":"Encyclopedia of Toxicology (Third Edition)"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0055","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jdcr.2016.05.011","article-title":"Exuberant inflammatory reaction to occlusion of topical 5-fluorouracil (FU) under a continuous positive airway pressure (CPAP) mask: a warning to dermatologists and patients","volume":"2","author":"Loyal","year":"2016","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060516","article-title":"Nano-vesicle based anti-fungal formulation shows higher stability, skin diffusion, biosafety and anti-fungal efficacy in vitro","volume":"12","author":"Deaguero","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0070","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0075","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0080","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0085","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1021\/acsbiomaterials.1c00322","article-title":"Ionic liquid-enabled topical delivery of immunomodulators","volume":"7","author":"Zhao","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0090","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0095","article-title":"Ionic liquids as potential enhancers for transdermal drug delivery","volume":"516","author":"Monti","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0100","doi-asserted-by":"crossref","DOI":"10.1021\/acsbiomaterials.9b00243","article-title":"The influence of water on choline-based ionic liquids","volume":"5","author":"Tanner","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","article-title":"Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis","volume":"84","author":"Koopman","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13402-018-0397-1","article-title":"Induction of apoptosis via proteasome inhibition in leukemia\/lymphoma cells by two potent piperidones","volume":"41","author":"Contreras","year":"2018","journal-title":"Cell. Oncol. (Dordr)."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073508","article-title":"Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia\/lymphoma cells","volume":"8","author":"Robles-Escajeda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0022-1759(92)90089-C","article-title":"Determination of monoclonal antibody specificity by immunoadsorption and Western blotting","volume":"152","author":"Schuh","year":"1992","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0135","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/elps.200700002","article-title":"Multistrip Western blotting to increase quantitative data output","volume":"28","author":"Aksamitiene","year":"2007","journal-title":"Electrophoresis."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1914426116","article-title":"Oral ionic liquid for the treatment of diet-induced obesity","author":"Nurunnabi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0145","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1021\/nn402043c","article-title":"In vivo biodistribution and toxicology of carboxylated graphene quantum dots","volume":"7","author":"Nurunnabi","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0150","series-title":"Immunohistochemistry: five steps to publication-quality images","first-page":"1","author":"Fisher","year":"2021"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0155","author":"Abcam"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0160","author":"Imahej"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2018.09.042","article-title":"A new ligand of CD105 screened out by phage display technology provides a reliable identification of recurrent or metastasizing pleomorphic adenoma from pleomorphic adenoma","volume":"65","author":"Yu","year":"2018","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0170","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0175","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/cdd.2012.105","article-title":"The secrets of the Bcl-2 family","volume":"19","author":"Garc\u00eda-S\u00e1ez","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0185","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.3390\/ijms21176267","article-title":"Ionic liquids toxicity-benefits and threats","volume":"21","author":"Flieger","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0190","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1021\/je101040p","article-title":"Solubilities of pharmaceutical compounds in ionic liquids","volume":"56","author":"Smith","year":"2011","journal-title":"J. Chem. Eng. Data"},{"key":"10.1016\/j.jconrel.2022.07.035_bb0195","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1039\/a606508b","article-title":"Intrinsic molecular fluorescence of lactate dehydrogenase: an analytical alternative for enzymic determination of pyruvate","volume":"122","author":"de Marcos","year":"1997","journal-title":"Analyst."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0200","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","article-title":"Mechanisms of apoptosis","volume":"157","author":"Reed","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2006.03.016","article-title":"Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer","volume":"247","author":"Thomadaki","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0210","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0215","first-page":"3739","article-title":"Studying navitoclax, a targeted anticancer drug, in healthy volunteers \u2013 ethical considerations and risk\/benefit assessments and management","volume":"34","author":"Xiong","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0220","first-page":"117","article-title":"Emulgel: a surrogate approach for topical used hydrophobic drugs","volume":"1","author":"Khullar","year":"2011","journal-title":"IJPBS."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0225","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.biomaterials.2010.03.057","article-title":"Targeted near-IR QDs-loaded micelles for cancer therapy and imaging","volume":"31","author":"Nurunnabi","year":"2010","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0230","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fcell.2020.00354","article-title":"The senolytic drug navitoclax (ABT-263) causes trabecular bone loss and impaired osteoprogenitor function in aged mice","volume":"8","author":"Sharma","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0235","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-139247","article-title":"A phase 3, open-label, randomized study evaluating the efficacy and safety of navitoclax plus ruxolitinib versus best available therapy in patients with relapsed\/refractory myelofibrosis (TRANSFORM-2)","volume":"136","author":"Dilley","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0245","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5603\/FHC.a2016.0016","article-title":"Lymphangioinvasion in routine H&E staining is strongly associated with poor clinical outcome in lymph node-negative cutaneous melanoma patients","volume":"54","author":"Donizy","year":"2016","journal-title":"Folia Histochem. Cytobiol."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0255","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0260","doi-asserted-by":"crossref","first-page":"e1721","DOI":"10.1038\/cddis.2015.97","article-title":"BCL-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0270","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1021\/acs.molpharmaceut.1c00468","article-title":"Improving dermal delivery of rose bengal by deformable lipid nanovesicles for topical treatment of melanoma","volume":"18","author":"Demartis","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.035_bb0275","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1021\/acsnano.8b03800","article-title":"Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma","volume":"12","author":"Jiang","year":"2018","journal-title":"ACS Nano"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200462X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200462X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:33:53Z","timestamp":1759163633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592200462X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":55,"alternative-id":["S016836592200462X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}